Profit From The Grey Plague
It's an often-stated, but rarely-used investment truth: Get in front of a major trend and ride it for profits as the mainstream media and investors inevitably join the party.
It's seldom followed because most investors simply can't read trends properly. Yet in the following pages I'll show you exactly how to do just that. And why it could change your life.
You see, there's a once in a generation demographic shift underway in the US. And understanding it will mean truly gigantic profits for a select few.
Back on November 30, 2007, I presented my thesis on why I thought biotechnology was at the cusp of its biggest big bull yet. Now, that's saying a lot, considering an average biotech bull goes up 600% or more.
But my thesis was quite simple: A month-and-a-half earlier, a woman named Kathleen Casey-Kirschling was the first baby boomer to file for Social Security benefits.
Little did anybody know, this marked the day that the 21st century's biggest bull market began.
The numbers are staggering. . .
An average of 10,000 baby boomers is set to file for Social Security every single day for the next 20 years!
And within this population of baby boomers, diseases like Alzheimer's are downright distressing: 1,217 Americans are diagnosed with Alzheimer's every day... 8,518 every week... 444,205 every year!
It's estimated that 13.4 million Americans will suffer with Alzheimer's in the coming years. So many people are going to be affected by this disease, that we're calling it "The Gray Plague."
To call this a mega-trend would be an understatement. Indeed, the Alzheimer's drug market alone is worth over $5 billion per year.
The good news behind all of this is that I've discovered an early-stage company that will almost surely benefit from this mega-trend. In fact, the potential is as big as I've ever seen...
That's why I'm here today to tell you it's high time to buy biotechnology... and to buy the small biotech company developing a cure for "The Gray Plague."
The company is a biotech called Anavex Life Sciences (AVXL). You can currently buy Anavex while it's still trading under $3 a share. I expect Anavex to be trading for more than $28 a share within 24 months. I'll explain why in a minute, but first you need know why the biotech sector is the hottest sector in the market today.
That's right, if you haven't noticed, biotech is the hottest sector in the market today. Hotter than oil. . . hotter than gold. . and hotter than renewable energy.
This is a 6-month chart for the NYSE Arca Biotechnology Index:
Even with Obama pushing for health care reform, the bull market in biotech is running hard.
Because regardless of health care reform, older Americans will need constant medical care. Somebody is going to pay for medical care. . . whether it's the federal government vis-à-vis the taxpayer. . . or the health insurance companies. . . or the customer.
And big pharmaceutical companies like Johnson & Johnson and Pfizer know this. . . and that's why they are positioning themselves for the future.
Even as you read this, pharmaceutical companies - sitting on record cash reserves - are on a biotech buying binge:
Medarex, a small biotechnology company that was trading for less than $4 a share last March, received a $16 tender offer from Bristol Meyers on July 28.
Johnson & Johnson bought out Cougar Biotechnology for just under $1 billion in May.
Celldex Therapeutics announced its plan to acquire CuraGen for $94.5 million.
Novartis and Pfizer also did some international shopping in India and Austria, respectively.
And in March of this year, Roche acquired biotech giant Genentech.
It's no secret that investing in the right biotech stock can give you sudden and lasting wealth.
Just this past March, investors in a small biotech company called Dendreon saw for themselves the wealth-producing power of biotechnology.
Check out Dendreon's chart:
A $10,000 investment in March turned into $100,000 by September!
Here's the kicker: I think Anavex Life Sciences is the next Dendreon.
Before the biotech bull market shifts into high gear, I want you to buy Anavex for massive gains in the months and years ahead. Because it's imperative that we position ourselves ahead of the crowd.
Government Proposes an Alzheimer's Czar
This past July, a research report was released that confirmed Alzheimer's cases are rising at an epidemic pace.
And it's easy to see why. . .
The senior citizen cohort is the fastest growing contingent in America today.
In fact, it's the fastest growing segment of society in the western world.
In the U.S. alone, over 444,000 new cases of Alzheimer's are diagnosed each year... adding to the already five million cases that exist today.
Now here's were it gets really alarming: $100 billion is spent annually in America to cover Alzheimer's treatment.
And those costs are rising - fast.
The situation has gotten so drastic that on July 29, Senators Mel Martinez and Evan Bayh proposed a bill that would create a national Alzheimer's Office in the White House. . . with the creation of an "Alzheimer's Czar."
The whole goal of this policy is to "accelerate the development of cutting-edge medical treatments and drugs to fight Alzheimer's. . ."
My favorite play in the Alzheimer's space: Anavex Life Sciences (AVXL: OTCBB - $2.70).
In July 2009, an independent biotech analyst report on Alzheimer's said:
At early levels, ANAVEX seems to be an extremely promising approach if its impressive preclinical results are confirmed in the incoming human clinical trials. In fact, there are essentially no other early stage public companies with new concepts in Alzheimer's or with concepts that have shown some traction, while several concepts have already failed.
Anavex appears to be the one of the only companies - if not the only company - pursuing the most promising path to an Alzheimer's cure. It is countering oxidative stress by targeting sigma receptors.
If you've read my previous reports on Anavex, I explain sigma receptors. These receptors are protein molecules that exist in or near the surface of cells, and are vital in receiving cell expressions.
It's been confirmed that sigma receptors play a role in a vast number of conditions and offer as many therapeutic opportunities. Some are involved in pain control, going back to sigma receptors' roots. Others have oncological value treating cancers. Anavex has 30 solid candidates in varying states of development.
What that means is, this company has a host of potential drug compounds, which could treat ailments from cancer to depression to alzheimer's. To have a platform this promising within such a small company is almost unheard of.
The sigma receptor approach is the brainchild of Dr. Alexandre Vamvakides, who has spent 30 years in research, focusing on the therapeutic/pharmacological areas of nootropes, anti-neurodegenerative (anti-Alzheimer's), anti-epileptic, anti-depressive and prototype molecules.
The author of 80+ published scientific papers, he has worked at the Institut National de la Sante et de la Recherche Medicale in Paris, France, University of Athens (Greece), Ciba-Geigy (Basel, Switzerland), Sanofi (Montpellier, France), and many other European research labs for the discovery and development of new concepts in the therapeutic areas of Alzheimer's.
I was so excited about the research being done by Dr. Vamvakides and Anavex that I hopped on a plane to Athens, Greece to get a firsthand look at the company's technology platform.
This is me and Dr. Vamvakides in the Anavex lab in Athens... and when it comes to biotechnology research and reputation, he's a giant among his peers.
Do yourself a favor... do a Google search of his name and read the independent praise of his work.
So let me be very clear about this: All of his experience and expertise is about to explode onto the market at a single moment in history.
Anavex is a microcap stock with huge upside potential - either as a pure play on Alzheimer's or as a takeover candidate. And it's one of those plays that offer true 100-to-1 profit potential. I rate Anavex a strong buy at current levels.
Just this week the company released news on its Phase I human trials for Anavex 2-73, the company's leading Alzheimer's drug candidate. By year-end, we the company will be closer to the next stage, and will most certainly come under review from the larger biotech and pharmaceutical companies.
That's when things will really start to heat up. And remember, this is just one part of the company's platform. I expect to hear more from Anavex on their other compounds in the weeks and months ahead.
P.S. If you want more information about Anavex and its unique approach to curing Alzheimer's, visit the company's website at www.anavex.com. Or call them at:
Shareholder & Media Relations
Outside North America: (416) 489-0092
You can download the PDF version here: Profit From The Grey Plague
The Best Free Investment You'll Ever Make
Sign up for the free Wealth Daily
In each issue, you'll get our best investment research, designed to help you build a lifetime of wealth, minus the risk.
By signing up, you'll instantly receive our new report: North America Shale Dividend Guide.
... Finding The Most Profitable Investing Opportunities For Your Portfolio. We Protect Your Privacy
, Copyright © 2013, Angel Publishing LLC
. All rights reserved. The content of this site may not be redistributed without the express written consent
of Angel Publishing. Individual editorials, articles and essays appearing on this site may be republished, but only with full attribution of both the author and
Wealth Daily as well as a link to www.wealthdaily.com. Your privacy is important to us -- we will never rent or sell your e-mail or personal information. No statement or
expression of opinion, or any other matter herein, directly or indirectly, is an offer or the solicitation of an offer to buy or sell the securities or financial
instruments mentioned. While we believe the sources of information to be reliable, we in no way represent or guarantee the accuracy of the statements made herein.
does not provide individual investment counseling, act as an investment advisor, or individually advocate the purchase or sale of any security or investment. Neither the publisher nor the editors are registered investment advisors. Subscribers should not view this publication as offering personalized legal or investment counseling. Investments recommended in this publication should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company in question.